thalidomide-peg-2-nh2

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker, incorporating a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for PROTAC technology applications.

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthetic conjugate that combines a Thalidomide-based cereblon ligand and a linker, commonly utilized in PROTAC technology. This compound serves as a connector between the target protein and the E3 ligase, facilitating targeted protein degradation.

Thalidomide-PEG2-NH2 is a chemically synthesized E3 ligase ligand-linker conjugate consisting of a ligand derived from Thalidomide-based cereblon and a linker commonly employed in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating a Thalidomide-based cereblon ligand and a linker. This compound is used in the synthesis of PROTACs.

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines a Thalidomide-based cereblon ligand with a two-unit PEG linker for use in PROTAC technology[1].

Thalidomide-O-amido-PEG3-C2-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand based on Thalidomide and a 2-unit PEG linker for use in PROTAC technology[1].

Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology[1].

Thalidomide-O-amido-PEG2-C2-NH2, which combines an E3 ligase ligand with a linker, serves as an immunomodulator for cancer treatment.

Thalidomide-O-amido-PEG-C2-NH2 is a synthesized conjugate formulation designed as an E3 ligase ligand-linker conjugate, incorporating a cereblon ligand based on Thalidomide and a linker component commonly used in PROTAC technology.

Thalidomide-Piperazine-PEG2-NH2 is a synthetic E3 ligase ligand-linker conjugate combining the cereblon ligand derived from Thalidomide with a linker commonly used in PROTAC technology.

Thalidomide-amido-PEG2-NH2 is a synthetic conjugate combining the Thalidomide-based cereblon ligand with a (PEG2)-NH2 linker, commonly used in PROTAC technology.

Thalidomide-NH-PEG1-NH2 hydrochloride (4-[(2-(2-Aminoethoxy)ethyl)amino]-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione HCl) is a synthetic E3 ligase ligand-linker conjugate that incorporates the Thalidomide-based cereblon ligand and a linker[1].